2023年8月3日,

Tenpoint療法——一個生物科技公司追求vision-restoring工程細胞療法和體內重組解決退化性眼疾病——最近宣布推出7000萬美元的融資發展再生醫學平台係列取代多種細胞類型繼承和與年齡有關的症狀的。資金輪係列包括來自英國病人的新投資資本和資金從所有種子投資者,包括f '資本、Sofinnova夥伴,啟明創投合作夥伴美國八公路和倫敦大學學院的科技基金等等。f '和Sofinnova夥伴早期投資者支持成立公司的運營發展和技術擴張。公司基礎上成立的開創性工作科學創始人眼科醫院從倫敦大學眼科研究所,研究所de la願景在巴黎,和華盛頓大學的開發工程細胞療法和執行轉化研究建立概念驗證。基於這些成就,Tenpoint推進方法生成專門的眼部細胞體外和體內。Tenpoint由再生醫學和眼科專家。作為首席執行官,艾迪Anglade,醫學博士,帶著幾十年的經驗在臨床眼科疾病發展與重大的未滿足的需求。Tenpoint創始CEO的凡妮莎王博士領導的融資公司,將繼續支持組織戰略顧問。公司以前名叫大衛•蓋伊眼科創新者醫學博士主持董事會。蓋伊博士目前擔任首席執行官EyeBio和以前作為IVERIC生物的執行董事長,他創立的一家公司Ophthotech之下。 As co-founder, CEO, and director of Eyetech Pharmaceuticals, he oversaw the development and commercialization of Macugen® (pegaptanib sodium), the first anti-VEGF pharmacological treatment approved by the FDA for treatment of wet AMD. KEY QUOTES: “Cell-based therapeutics represent an ideal modality for degenerative ocular diseases since most vision loss results from damaged or missing tissue. In recent years, a number of new technological advancements have converged to make this modality both clinically viable and scalable. At Tenpoint, we are focused exclusively on the eye and on harnessing recent advances in regenerative biology to advance our therapies as we work to change the future for people with vision loss by addressing its underlying causes.” — Eddy Anglade, MD, Chief Executive Officer of Tenpoint “Tenpoint has great potential to lead ophthalmology into a new era which will fully replace cells lost to degenerative conditions rather than merely endeavoring to slow the processes that drive vision loss. This offers the potential for more complete restoration of sight and for curative treatments able to eliminate the underlying cause of disease.” — Dr. Guyer “Tenpoint’s mission is a global one. We are delighted to have provided international company creation support to launch such a visionary company.” — Alex Pasteur, PhD, Partner at F-Prime Capital “As one of the company’s seed investors, we are pleased to have played a founding role in developing Tenpoint from its inception. Tenpoint stands out in the realm of regenerative medicine, with an innovative approach that could ultimately provide a transformative cure to many causes of blindness for millions of patients around the world.” — Graziano Seghezzi, PhD, Managing Partner at Sofinnova Partners Trending on Pulse 2.0